Myfembree Shortage: A Provider Briefing for 2026

Myfembree (Relugolix 40 mg / Estradiol 1 mg / Norethindrone Acetate 0.5 mg) continues to be a first-line oral option for managing heavy menstrual bleeding from uterine fibroids and moderate to severe endometriosis-associated pain in premenopausal women. However, providers across the country are hearing a consistent concern from patients: they can't find it at the pharmacy.

This article provides a concise overview of the current Myfembree availability landscape, the factors affecting patient access, prescribing considerations, and tools to help your patients locate their medication.

Current Supply Status: Timeline and Context

Myfembree received FDA approval in May 2021 for uterine fibroids and was subsequently approved for endometriosis-associated pain in 2022. It is manufactured by Myovant Sciences (a subsidiary of Sumitovant Biopharma/Sumitomo Pharma) in collaboration with Pfizer.

As of early 2026, Myfembree is not listed on the FDA Drug Shortage Database. There is no reported manufacturing disruption or raw material constraint. The availability challenges patients experience are driven by downstream distribution and pharmacy-level stocking decisions rather than upstream supply issues.

A generic formulation (Relugolix/Estradiol/Norethindrone Acetate) has entered the market, which is gradually increasing overall supply. However, generic distribution is still expanding and not universally available at all pharmacy locations.

Prescribing Implications

The practical difficulty patients face in filling Myfembree prescriptions has several clinical implications for prescribers:

Treatment Adherence and Continuity

Gaps in Myfembree therapy can lead to return of symptoms — increased menstrual bleeding, pelvic pain, and hormonal fluctuation. When patients cannot fill their prescriptions promptly, adherence suffers. Consider proactively discussing pharmacy access with patients at the time of prescribing.

Prior Authorization Burden

Most commercial and Medicare Part D plans require prior authorization for Myfembree. Some impose step therapy requirements, potentially requiring documentation of inadequate response to NSAIDs, hormonal contraceptives, or other first-line therapies. Building prior authorization workflows into your practice — or utilizing prior authorization support services — can reduce delays for patients.

24-Month Treatment Limitation

Myfembree carries a recommended maximum treatment duration of 24 months due to the risk of continued bone mineral density loss. Gaps in therapy due to pharmacy access issues can complicate treatment planning and timelines. Document any treatment interruptions and reassess bone health as appropriate.

Boxed Warning Considerations

Myfembree carries a boxed warning for thromboembolic disorders and vascular events. The estrogen and progestin components increase the risk of DVT, PE, stroke, and MI, particularly in women over 35 who smoke and those with cardiovascular risk factors. This boxed warning should be discussed with every patient and documented in the medical record.

The Availability Picture

The core challenge is not supply — it's stocking. Here's what's driving patient access difficulties:

• Retail pharmacy stocking patterns: Large chain pharmacies (CVS, Walgreens, Rite Aid) prioritize high-volume medications. Specialty drugs like Myfembree, with a retail price of $1,200–$1,700 per 28-day supply, are often not kept in regular inventory.
• Specialty pharmacy channeling: Some insurance plans channel Myfembree through designated specialty pharmacies. While this can improve access for patients in those plans, it can create confusion when prescriptions are sent to retail pharmacies.
• Generic distribution ramp-up: The generic Relugolix/Estradiol/Norethindrone Acetate formulation is available but not yet universally stocked. Distribution networks are still building out.
• Regional variation: Availability varies significantly by geography. Urban areas with more specialty pharmacy options tend to have better access than rural regions.

Cost and Access Landscape

Understanding the cost picture helps in counseling patients:

• Brand retail price: $1,500–$1,700/month
• Generic with coupon: ~$1,150–$1,207/month (GoodRx, SingleCare)
• Copay Assistance Program: Myovant offers a copay assistance program for commercially insured patients — eligible patients may pay as little as $0 per fill (via TrialCard)
• Patient Assistance Program: For uninsured/underinsured patients, Myovant offers a separate patient assistance program
• Medicare Part D: Covered by many plans with tiered copays; the 2025 out-of-pocket cap of $2,000/year may reduce annual patient burden

For detailed cost-saving guidance to share with patients, see: How to Save Money on Myfembree in 2026.

Tools and Resources for Providers

Medfinder for Providers

Medfinder offers a provider-facing tool that shows real-time pharmacy availability for Myfembree by location. This can be integrated into your practice workflow to help patients identify stocking pharmacies before they leave the office.

Specialty Pharmacy Referrals

Establishing relationships with 1-2 specialty pharmacies that reliably stock Myfembree can significantly improve your patients' experience. Consider sending prescriptions directly to these pharmacies rather than retail chains.

Manufacturer Resources

Myovant Sciences provides prescriber support through myfembreehcp.com, including prescribing information, prior authorization support, and patient financial assistance enrollment.

Alternative Therapies

When Myfembree is unavailable or not tolerated, consider the following alternatives:

• Oriahnn (Elagolix/Estradiol/Norethindrone Acetate) — Similar mechanism with add-back therapy; FDA-approved for uterine fibroids only; twice-daily dosing
• Orilissa (Elagolix) — GnRH antagonist without add-back; FDA-approved for endometriosis pain; increased bone loss risk
• Lupron Depot (Leuprolide Acetate) — Injectable GnRH agonist; FDA-approved for both conditions; initial flare effect; typically short-term use

For a patient-facing comparison, see: Alternatives to Myfembree.

Looking Ahead

Several trends may improve Myfembree access through 2026 and beyond:

• Continued expansion of generic distribution networks
• Growing specialty pharmacy infrastructure for women's health medications
• Digital tools like Medfinder reducing the information gap between prescribers and available pharmacy stock
• Potential additional generic entrants adding competitive pressure on pricing

Final Thoughts

While Myfembree is not in a formal shortage, the practical barriers to patient access are real and clinically significant. Proactive communication about pharmacy access, early prior authorization submissions, and leveraging tools like Medfinder for Providers can meaningfully improve the patient experience. For a step-by-step operational guide, see our companion article: How to Help Your Patients Find Myfembree in Stock.